Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
163 hedge funds and large institutions have $1.08B invested in Verve Therapeutics in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 74 increasing their positions, 40 reducing their positions, and 20 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 40
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
4% more funds holding
Funds holding: 157 → 163 (+6)
4% more capital invested
Capital invested by funds: $1.05B → $1.08B (+$37.5M)
0.84% less ownership
Funds ownership: 98.46% → 97.62% (-0.84%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$18.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.3M |
| 3 |
BlackRock
New York
|
+$12.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$13.1M |
| 2 |
JP Morgan Chase
New York
|
-$7.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.62M |
| 4 |
Jane Street
New York
|
-$3.25M |
| 5 |
Squarepoint
New York
|
-$2.13M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PO
176
PBCay One
Dubai,
United Arab Emirates
| – | -$95.7K | -6,864 | Closed |
|
|
IUHSA
177
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| – | -$26.2K | -1,878 | Closed |
|
|
SO
178
STRS Ohio
Columbus,
Ohio
| – | -$13K | -1,000 | Closed |
|
|
ME
179
McIlrath & Eck
Arlington,
Washington
| – | -$1.05K | -75 | Closed |
|
|
BIA
180
Bell Investment Advisors
Oakland,
California
| – | -$586 | -42 | Closed |
|
|
CPG
181
Cornerstone Planning Group
Fairfield,
New Jersey
| – | -$28 | -2 | Closed |
|
182
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$53 | +4 | +13% |
|
VERV Hedge Fund Activity: Q1 2024 in Review
163 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2024, worth a combined $1.08B — up 3.6% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VERV positions and 20 closed out — a net gain of 7 holders — while 74 added to existing stakes and 40 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $18.6M. The largest seller was ARK Investment Management, cutting an estimated $13.1M.
- 163 institutional investors held Verve Therapeutics (VERV) as of Q1 2024, up from 157 in Q4 2023.
- Funds reported $1.08B of Verve Therapeutics stock for Q1 2024, up 3.6% quarter-over-quarter.
- 27 funds opened new Verve Therapeutics positions in Q1 2024 and 20 closed out, a net change of +7 holders.
- The largest Verve Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $18.6M added.
- The largest Verve Therapeutics seller in Q1 2024 was ARK Investment Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2024.